Analyst rates DiaMedica Therapeutics a Buy: ReMEDy2's Q1 2027 interim could prompt a stop on strong efficacy; Nov.
MINNEAPOLIS, October 19, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time.
Detailed price information for Diamedica Therapeutics Inc (DMAC-Q) from The Globe and Mail including charting and trades.
MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This is the newest page. Registered accounts read further back.